Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab

Arthritis and Rheumatism

Volumn 48, Issue 3, 2003, Pages 780-790

  Zou, Jianxiang ^a   Rudwaleit, Martin ^a   Brandt, Jan ^a   Thiel, Andreas ^b   Braun, Jürgen ^a,c   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatology Research Center   (Germany)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 4; IONOMYCIN; MONOKINE; PEPTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSTIMULATION; INTERMETHOD COMPARISON; INTRACELLULAR TRANSPORT; MONONUCLEAR CELL; PEPTIDE ANALYSIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037333440     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10847     Document Type: Article

References (32)

1. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26 Suppl 57:16-21.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
3. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6:225-30.
4. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, ATTRACT Study Group. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
6. Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
7. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
8. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989;96:339-44.
9. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
10. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
11. Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
12. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
13. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
14. Sieper J, Kingsley G, Palacios-Boix A, Pitzalis C, Treharne J, Hughes R, et al. Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum 1991;34:588-98.
15. Buzas EI, Mikecz K, Glant TT. Aggrecan: a target molecule of autoimmune reactions. Pathol Oncol Res 1996;2:219-28.
16. Leroux JY, Guerassimov A, Cartman A, Delaunay N, Webber C, Rosenberg LC, et al. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound deratansulfate in vitro and in vivo. J Clin Invest 1996;97:621-32.
17. Zou JX, Rudwaleit M, Thiel A, Radbruch A, Zhang Y, Braun J, et al. Cellular immune response to the cartilage-derived autoantigen aggrecan in ankylosing spondylitis and rheumatoid arthritis [abstract]. Arthritis Rheum 2001:44 Suppl 9:S236.
18. Jung G, Beck-Sickinger AG. Multiple peptide synthesis methods and their applications. Angew Chem Int Ed Engl 1992;31:367-83.
19. Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000;43:2834-42.
20. Baeten D, van Damme N, van den Bosch F, Kruithof E, de Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001;60:750-5.
21. Sieper J, Braun J. Pathogenesis of spondylarthropathies: persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995;38:1547-54.
22. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-8.
23. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
24. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
25. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001;15:212-22.
26. Prehn JL, Landers CJ, Targan SR. A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J Immunol 1999;163:4277-83.
27. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RAW, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:2166-73.
28. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
29. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors. Ann Rheum Dis 2001;60:133-9.
30. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Upregulation of the production of TNFα and IFN-γ by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis. In press.
31. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998;55:613-20.
32. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.